Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer

• Published in: Head & neck Vol. 45; no. 9; pp. 2207 - 2216
• Main Authors: Han, James, Zakeri, Kaveh, Raab, Gabriel, Hesse, Jennifer, Shamseddine, Achraf, Chen, Linda, Yu, Yao, Kang, Jung Julie, McBride, Sean M., Riaz, Nadeem, Tsai, C. Jillian, Gelblum, Daphna, Sherman, Eric J., Wong, Richard J., Michel, Loren, Lee, Nancy Y.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-09-2023; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin; Carboplatin - therapeutic use; Chemoradiotherapy; Chemoradiotherapy - adverse effects; Cisplatin; Cisplatin - therapeutic use; cisplatin ineligible; concurrent carboplatin and paclitaxel; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Humans; locally advanced head and neck cancer; Metastases; Middle Aged; Neoplasm Recurrence, Local - drug therapy; older age and comorbidities; Paclitaxel; Radiation therapy; Squamous Cell Carcinoma of Head and Neck - drug therapy; Survival; locally advanced head and neck cancer; older age and comorbidities; cisplatin ineligible; concurrent carboplatin and paclitaxel
• ISSN: 1043-3074; 1097-0347; 1097-0347
• DOI: 10.1002/hed.27456

Background
We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
Materials and Methods
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.
Results
Sixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.
Conclusions
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients.